A Phase 3 interventional study of Triamcinolone acetonide in Proliferative Vitreoretinopathy, sponsored by Shahid Beheshti University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2006-10-12.
Sponsored by Shahid Beheshti University of Medical Sciences · Phase 3, Interventional, and Treatment
To evaluate the effect of triamcinolone acetonide in silicone-filled eyes on the outcome of surgery for PVR.
35 studies on the registry are indexed under Vitreoretinopathy, Proliferative; 9 are open to participants now.
Browse Vitreoretinopathy, Proliferative studies →Shahid Beheshti University of Medical Sciences is the lead sponsor of 221 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single-operation retinal reattachment rate six
months after surgery.
Visual acuity
Retinal reproliferation
Intraocular pressure
Early silicone oil emulsification
This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vitreoretinopathy, Proliferative→
Shahid Beheshti University of Medical Sciences